On April 16, 2026, MeiraGTx Holdings plc reported successful 3-year results from its Phase 1 clinical study of AAV-hAQP1, showing significant improvements in patients with radiation-induced xerostomia. The treatment demonstrated a 62% improvement in the Xerostomia Questionnaire scores maintained over 36 months, indicating a potential annual revenue of $2.0 billion in the U.S.